Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver Metastasis
To evaluate the safety and efficacy of sintilimab combined with regorafenib and HAIC in patients with colorectal liver metastasis who failed second-line therapy
Colorectal Cancer|Liver Metastasis
DRUG: HAIC|DRUG: Sintilimab|DRUG: Regorafenib
Adverse Events (AEs), Defined as the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0, up to 24 months|Overall response rate ( ORR), Defined as proportion of patients who have a best response of CR or PR, up to 24 months
Disease control rate (DCR), Defined as proportion of patients who have a best response of CR, PR or SD, up to 24 months|Duration of response (DoR), Defined as the time from first confirmed response (CR or PR) to the date of the first documented tumor progression or death due to any cause, whichever occurs first., up to 24 months|Progression free survival (PFS), Defined as the time from enrollment to disease progression or death, whichever occurs first, up to 28 months|Overall survival (OS), Defined as the time from the date of treatment start to the date of death, up to 28 months
To evaluate the safety and efficacy of sintilimab combined with regorafenib and HAIC in patients with colorectal liver metastasis who failed second-line therapy